Zura Bio Limited

Zura Bio Limited is a clinical-stage, multi-asset immunology biotechnology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with significant unmet medical needs. The company's mission is to develop and deliver transformative therapies for patients suffering from severe inflammatory and autoimmune conditions. Zura Bio Limited is headquartered in Henderson, Nevada, USA, with team members also located in the UK.

The company's pipeline comprises three clinical-stage assets: tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Tibulizumab (ZB-106), a bispecific antibody designed to neutralize both IL-17A and BAFF, is currently undergoing two Phase 2 clinical trials: TibuSHIELD for hidradenitis suppurativa and TibuSURE for systemic sclerosis. Crebankitug (ZB-168), a fully human IgG1 monoclonal antibody targeting interleukin-7 receptor alpha, and torudokimab (ZB-880), a fully human IgG4 monoclonal antibody targeting interleukin-33, have both completed Phase 1 clinical studies.

In recent leadership changes, Sandeep Kulkarni, M.D., was appointed Chief Executive Officer effective January 21, 2026. Zura Bio Limited successfully closed a $144 million public offering in February 2026, which is expected to fund operations through at least the end of 2028. Topline data from the Phase 2 TibuSHIELD trial is anticipated in Q4 2026, with results from the TibuSURE study expected in H1 2027. The company is publicly traded on the Nasdaq Capital Market under the ticker symbol ZURA.